Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 11/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | USP5 | P45974 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158841 | 0.95 | CACNA1G (0.53) | CACNA1GCYP3A4CYP2D6KCNH2HRH3 | |
| SCHEMBL14015184 | 0.92 | CYP3A4 (0.45) | CACNA1GKDM4EALDH1A1GLAGAA | |
| SCHEMBL13158843 | 0.89 | USP5 (0.50) | ALDH1A1GAAUSP5LMNA | |
| SCHEMBL12437829 | 0.88 | CACNA1G (0.54) | CACNA1GKDM4EALDH1A1GLAGAA | |
| SCHEMBL13158840 | 0.85 | CACNA1G (0.51) | CACNA1GKDM4EALDH1A1GLAGAA | |
| SCHEMBL12437828 | 0.85 | CACNA1G (0.55) | CACNA1GKDM4EALDH1A1GLAGAA | |
| SCHEMBL13158844 | 0.84 | F10 (0.49) | CACNA1GALDH1A1GAAUSP5HTR3A | |
| SCHEMBL13158839 | 0.83 | CACNA1G (0.46) | CACNA1GKDM4EALDH1A1GLAGAA | |
| SCHEMBL12437833 | 0.83 | CACNA1G (0.60) | CACNA1GCYP2D6HTR3A | |
| SCHEMBL12437963 | 0.83 | CACNA1G (0.52) | CACNA1GKDM4EALDH1A1GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2141994-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | Avalon Pharmaceuticals (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008133975-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008133975-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | TP53, BCOR, HPGDS | CACNA1G 4812/4885KDM4E 1882/4885ALDH1A1 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.